<DOC>
	<DOCNO>NCT00414544</DOCNO>
	<brief_summary>This randomize , double-blind pivotal study evaluate safety effectiveness CosmetaLife injectable dermal filler correction wrinkle fold , nasolabial fold ( i.e. , smile line ) .</brief_summary>
	<brief_title>Evaluation Safety Efficacy CosmetaLifeâ„¢ Correction Nasolabial Folds</brief_title>
	<detailed_description>Patients negative reaction skin test result randomize receive CosmetaLife one nasolabial fold Control nasolabial fold opposite side face ( split face design ) . Each subject serve control , allow comparison outcome contralateral side . Patients follow 2 week 3 , 6 , 9 12 month post treatment assessment safety effectiveness .</detailed_description>
	<criteria>1 . Patients 18 year age old 2 . Patients moderate nasolabial fold ( 34 WSRS scale ) 3 . Patients willing provide write informed consent participation study 4 . Patients willing abstain facial cosmetic procedure 12 month followup visit 1 . Patients aesthetic facial therapy within 6 month prior 2 . Patients reaction skin test 3 . Patients history autoimmune disorder , lidocaine reaction , allergy heparin , severe chronic allergy 4 . Patients current disease state effect immunoresponse , patient immunosuppressive therapy 5 . Patients active infection kind , skin disease , connective tissue disorder 6 . Patients pregnant lactate 7 . Patients enrol another investigational clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Nasolabial fold</keyword>
	<keyword>Dermal filler</keyword>
	<keyword>Injectable dermal filler</keyword>
	<keyword>Soft tissue augmentation</keyword>
</DOC>